[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zymeworks Inc (ZYME)

Zymeworks Inc (ZYME)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Zymeworks Inc 108 PATRIOT DRIVE SUITE A MIDDLETOWN DE 19709 USA

www.zymeworks.com Employees: 264 P: 302-274-8744

Sector:

Medical

Description:

Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.

Key Statistics

Overview:

Market Capitalization, $K 1,689,752
Enterprise Value, $K 1,648,592
Shares Outstanding, K 73,023
Float, K 48,553
% Float 66.49%
Short Interest, K 4,528
Short Float 6.20%
Days to Cover 7.61
Short Volume Ratio 0.45
% of Insider Shareholders 33.51%
% of Institutional Shareholders 92.89%

Financials:

Annual Sales, $ 105,970 K
Annual Net Income, $ -81,130 K
Last Quarter Sales, $ 2,410 K
Last Quarter Net Income, $ -44,160 K
EBIT, $ -114,050 K
EBITDA, $ -102,940 K

Growth:

1-Year Return 83.21%
3-Year Return 185.33%
5-Year Return -37.39%
5-Year Revenue Growth 172.07%
5-Year Earnings Growth 69.83%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.59 on 05/07/26
Next Earnings Date 08/06/26
Earnings Per Share ttm -1.37
EPS Growth vs. Prev Qtr -7.27%
EPS Growth vs. Prev Year -96.67%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

ZYME Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward 21.04
Price/Earnings to Growth N/A
Return-on-Equity % -37.97%
Return-on-Assets % -25.30%
Profit Margin % -76.56%
Debt/Equity 0.00
Price/Sales 15.95
Price/Cash Flow N/A
Price/Book 10.43
Book Value/Share 2.22
Interest Coverage -0.30
60-Month Beta 1.15
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.